Physiomics plc combines systems biology, PKPD and cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process. Virtual Tumour is a flexible in-silico model of cancer that has been used successfully to simulate a wide range of cancer types, cell lines, molecular targets and combinations of pharmaceutical and radiation therapy. The Company has worked in the small molecule as well as the biological space and has experience of traditional chemo, targeted chemo and immuno-therapies. The Company has completed over 50 projects with a range of commercial and academic clients including Lilly, Merck Inc, Merck KGaA, Bayer Technology Services, Sareum, ValiRx, Cancer Research Technologies, Cyclacel, Innovate UK, NIH, Oxford University and Cancer Research Technology. The Company is based in Oxford and has close ties to the University and Hospital located there.